Lovastatin in Treating Patients At High Risk of Melanoma

Inclusion Criteria: * Presence of at least 2 clinically atypical nevi on the body that are reasonably matched in regards to level of clinical atypia, or one atypical mole and another atypical mole \>= 8 mm in diameter (for this pair the two moles do not have to be closely matched and only one of them must be \>= 8 mm in diameter) * A history of melanoma is not required for study entry * Patients with completely resected stage I or II who have not received adjuvant therapy in the past 3 months * Eastern Cooperative Oncology Group (ECOG) performance status of 1 or better (Karnofsky \> 70%) * Leukocytes \>= 3,000/uL * Absolute neutrophil count \>= 1,500/uL * Platelets \>= 100,000/uL * Total bilirubin within normal institutional limits * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \[SGPT\]) =\< 2.5 X within normal limits * Creatinine within normal institutional limits * Ability to understand and the willingness to sign the written informed consent * Subjects willing and able to participate for the full duration of the study * For women of child-bearing potential (women are considered not of childbearing potential if they are at least 2 years post-menopausal and/or surgically sterile), she: * has been using adequate contraception (abstinence, intrauterine device \[IUD\], birth control pills, or spermicidal gel with diaphragm or condom) since her last menses and will use…